This article was originally published in The Rose Sheet
Lower consumption and inventory correction drives "sharp decline" in firm's fine fragrance and beauty care business, International Flavors and Fragrances says in an April 30 first quarter earnings release. Sales for fragrances were down 9% on a reported basis, and down 5% on a local currency basis. North American fragrance sales increased 2%, but sales in the Europe, Africa and Middle East regions plummeted 24% (16% in local currencies), company notes. "The fragrance team continues to win key projects and is building core capabilities that we expect will lead to future growth," says Chairman and CEO Robert Amen. Impact of foreign currency translation drove total sales down 6.2% to $560 mil. Net income declined 16% to $47.2 mil
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.